BC 22419 Roche This study is to evaluate effects of Aleglitazar on renal function in patient with Type 2 Diabetes and moderate renal inpairment, as compared to Actos Inclusion Criteria Type 2 diabetes with moderate renal function impairment Over 18 years Nil diabetic medication taking or on one diabetic medication, No more than 2 combination of diabetic medications eGFR > 30 and <60 Urine ACR <3 at screening BMI 25 - 35 (Asian 23) For more information: Meredith Porter 9926 6879; mrporter@nsccahs.health.nsw.gov.au

     Enroll for this clinical trial